MYGN:NASDAQ
Myriad Genetics Inc
$4.19
arrow_downward
-0.24%(-0.0100) 1D
Oct 9, 9:30:39 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MYGN...
Open
$4.18
High
$4.21
Low
$4.15
Mkt. cap
400.77M
Avg. vol.
2.03M
Volume
69.00
52-wk high
$8.59
52-wk low
$2.74
EPS
-$1.20
Beta
1.64
Shares outstanding
95.65M
No. of employees
3K
Open
$4.18
High
$4.21
Low
$4.15
Mkt. cap
400.77M
Avg. vol.
2.03M
Volume
69.00
52-wk high
$8.59
52-wk low
$2.74
EPS
-$1.20
Beta
1.64
Shares outstanding
95.65M
No. of employees
3K
News stories
From web sources and news partners
GuruFocus
·
21 hours ago
Myriad Genetics (MYGN) Partners with AstraZeneca and SOPHiA Gene
Investing.com
·
1 day ago
Myriad Genetics, SOPHiA partner on prostate cancer biomarker
PR Newswire
·
1 day ago
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
Stock Titan
·
1 day ago
A prostate cancer score may help group patients in treatment trials
Profile
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to a particular drug therapy, assess a patient's risk of disease progression and disease recurrence, and measure disease activity. Wikipedia
About Myriad Genetics Inc
CEOPaul J. Diaz | Paul J. Diaz
Employees2.7K
Founded1991
HeadquartersSalt Lake City, Utah, United States
SectorBiotechnology
Websitemyriad.com